Compliance SweepBack to stories →
← Back to stories
Governance & business operationsNew in this edition

FDA early alert: Intersurgical removes lots of 22mm Smoothbore breathing tubes and systems over connector disconnection and loss of ventilation risk

The Food and Drug Administration (FDA) posted an early alert on November 10, 2026 about Intersurgical Inc., which has told customers to remove listed lots of its 22mm Smoothbore breathing tubes and systems. Intersurgical sent the letter on November 3, 2026, telling customers to stop using and quarantine stock with the affected product and lot numbers and return it. Testing of internal stock found some products were made with too little solvent to secure the soft connectors to the tube. A connector that disconnects during use could cause loss of ventilation or compromised ventilation. As of November 3, 2026, the firm had reported no serious injuries or deaths.

A supply cart in a hospital corridor stands with drawers open showing bagged clear breathing tubing with blue connectors.
Illustrative artwork; not evidence of the actual people, products or events described.

Background

An FDA early alert notifies the public of a potentially high-risk device issue while FDA reviews it. Intersurgical 22mm Smoothbore breathing tubes and systems connect patients to machines that help them breathe; the firm acted after reports from markets outside the U.S. of soft connectors disconnecting from the tube.

Who this affects

Hospitals using Intersurgical 22mm Smoothbore breathing tubes and heated-wire, bilevel and exhalation-valve breathing systems (respiratory therapy, critical care, anesthesia, supply chain)

Why it matters

FDA and Intersurgical say to stop using and quarantine affected lots, which include heated-wire and bilevel breathing systems. Inference: respiratory therapy needs replacement circuits on hand. A disconnection during use could cause loss of or compromised ventilation, which may cause the patient to desaturate until ventilation is manually re-initiated.

Implementation playbook

  1. Immediately check breathing tube and circuit stock in respiratory therapy, critical care and anesthesia against the reference and lot numbers on the FDA page, stop using any match, quarantine any stock with the affected product and lot numbers, and share the notice with every unit that sets up ventilator, bilevel or heated-wire breathing circuits. The Intersurgical letter, as FDA reports it, says to discontinue use and quarantine immediately. Owner: Respiratory therapy and Supply chain. Due: immediately.
  2. Return the quarantined lots to Intersurgical. Owner: Supply chain. Due: 2026-11-21.
  3. Confirm replacement circuits are stocked for ventilated and bilevel patients. Owner: Respiratory therapy. Due: 2026-11-18.
  4. Report any connector disconnection or loss of ventilation to MedWatch and to risk management. Owner: Risk management. Due: at each event.

Scope and timing

Authority status
Other (FDA early alert)
Responsible owner
Respiratory therapy, Supply chain, Clinical engineering, Critical care
Publication date
2026-11-10
Other dates
2026-11-03 Intersurgical letter to affected customers; injury status as of 2026-11-03

Sources

Complete edition and supplemental material

This article in the complete report →

Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.

Read the entire Compliance Sweep report →

← Return to stories

Privacy preferences

Where enabled for this site, Cloudflare Web Analytics can send page-use and performance measurements to Cloudflare. This panel provides information and does not turn analytics on or off.

This panel stores no tracking choice and does not change your tool saves, screening, resets, reports or exports. Other sites have separate settings.

Read Privacy & Cookies